AR086881A1 - Derivados de picolinamida como agonistas del receptor cb2 - Google Patents
Derivados de picolinamida como agonistas del receptor cb2Info
- Publication number
- AR086881A1 AR086881A1 ARP120102046A ARP120102046A AR086881A1 AR 086881 A1 AR086881 A1 AR 086881A1 AR P120102046 A ARP120102046 A AR P120102046A AR P120102046 A ARP120102046 A AR P120102046A AR 086881 A1 AR086881 A1 AR 086881A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- cycloalkyl
- oxadiazolyl
- peri
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
Abstract
El compuesto de la fórmula (1) puede utilizarse como medicamento para el tratamiento de enfermedades tales como la aterosclerosis y la isquemia. Se provee también un método para su obtención.Reivindicación 1: Un compuesto de la fórmula (1) en la que: R1 es cicloalquilo, cicloalquilalcoxi, haloalcoxi, alcoxialcoxi, fenilo, halofenilo, haloalquilfenilo, fenilalquilo, halofenilalquilo, fenilhidroxialquilo, feniloxialquilo, fenilalcoxi, alcoxifenilo, halofeniloxi, piperidinilsulfonilo, tetrahidropiranilo, 3-alcoxi-azetidinilo, tetrahidropiranilalquilo, tetrahidropinanil-alcoxi, 1,1-dióxido de tetrahidrotiopiranilo, 1,1-dioxo-[1,2]-tiazinan-4-ilo, piperidin-2-onilo, tetrahidrofuranil-alcoxi, piridinilalcoxi, alquiloxetanilalcoxi, hidroxil-haloalquiloxi, halofenilhidroxialquilo, alquilsulfonilo, alquilsulfanilo o (halo)(haloalquil)fenilo; R2 es hidrógeno, halógeno, alquilo, haloalquilo, hidroxialquilo, cicloalquilo, hidroxicicloalquilo, alcoxi, haloalcoxi, alquilamino, haloalquilamino, tetrahidropiranilo, 1H-pirazolilo, pirrolidinilo, alquilpirrolidinilo, halo-pirrolidinilo, oxopirrolidinilo, haloazetidinilo, hidroxiazetidinilo, 1,1-dioxido-2-isotioazolidinilo, tetrahidrofuranilo, cicloalquilamino, hidroxioxetanilo, alquilsulfonilo, oxetanilo, 6-oxa-1-aza-espiro[3.3]-heptilo, 3,3-difluoro-2-oxo-azetidinilo, oxo-azetidinilo u oxo-pirrolidinilo; o R1 y R2 junto con el anillo al que están unidos forman un tetrahidroquinolinilo o alquiltetrahidroquinolinilo; uno de R3 y R4 es hidrógeno y el otro es -(CR5R6)m(CR7R8)n-R9; o R3 y R4 junto con el átomo de nitrógeno al que están unidos forman un piperidinilo, 1,1-dioxidotetrahidro-2H-tio-piranilo, tiomorfolinilo, 2-oxa-6-aza-espiro[3.3]heptilo o 1-hidroxialquilpirrolidinilo; R5 y R6 se eligen con independencia entre hidrógeno, alquilo, haloalquilo, cicloalquilo, cicloalquilalquilo, fenilo, piridazinilo, halofenilo, pirimidinilo, alquilsulfanilalquilo y alquilsulfonilalquilo; o R5 y R6 junto con el átomo de carbono al que están unidos forman un cicloalquilo, tetrahidropiranilo u oxetanilo; R7 y R8 se eligen con independencia entre hidrógeno, alquilo y cicloalquilo; R9 es alquilo, hidroxilo, ciano, carboxilo, alcoxicarbonilo, alquil[1,2,4]oxadiazolilo, oxazolilo, tiazolilo, [1,3,4]oxadiazolilo, cicloalquilo, fenilo, piridinilo, tetrahidropiranilo, alquil[1,2,4]tiadiazolilo, [1,2,4]-tiadiazolilo, alquilaminocarbonilo, alquiltetrahidropiranilo, alquilisoxazolilo, aminocarbonilo, morfolinilo, dihidrooxazolilo, [1,2,4]oxadiazolilo, hidroxicicloalquilo, alcoxicarbonilcicloalquilo, alcoxialcoxi, hidroxialquilcicloalquilo, alcoxipiridinilo, piperidinilo, hidroxipiperidinilo, hidroxialquilpiperidinilo, isoxazolilo, azetidina-carbonilo, alcoxialquilaminocarbonilo, cicloalquil-alquilaminocarbonilo, haloazetidinilcarbonilo, alquiloxopirrolidinilo, 1,1-dioxo-tetra-hidro-1l6-tiofenilo, 1,1-dioxo-tetrahidro-1l6-tiofenil-amino, amino[1,2,4]oxadiazolilo, 4-alquil-5-oxo-4,5-dihidro-[1,2,4]oxadiazolilo, nitro-benzo[1,2,5]oxadiazolilo, alquilsulfonilo, alquil[1,2,4]tiazolilo, hidroxialquilaminocarbonilo, oxotetrahidrofuranilo, (cicloalquilalquil)(alcoxicarbonil)amino, 2-oxo-[1,3]-oxazinanilo, haloalquilo o hidroxipirrolidinilaminocarbonilo; m es el número 0 ó 1; y n es el número 0, 1 o 2; o una sal o un éster farmacéuticamente aceptables del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011075606 | 2011-06-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR086881A1 true AR086881A1 (es) | 2014-01-29 |
Family
ID=46208600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120102046A AR086881A1 (es) | 2011-06-10 | 2012-06-08 | Derivados de picolinamida como agonistas del receptor cb2 |
Country Status (36)
Country | Link |
---|---|
US (2) | US9321727B2 (es) |
EP (2) | EP2718266B9 (es) |
JP (3) | JP5997265B2 (es) |
KR (1) | KR20140042848A (es) |
CN (2) | CN106349156B (es) |
AR (1) | AR086881A1 (es) |
AU (2) | AU2012266369B2 (es) |
BR (1) | BR112013031463A2 (es) |
CA (1) | CA2835745A1 (es) |
CL (1) | CL2013003486A1 (es) |
CO (1) | CO6811864A2 (es) |
CR (1) | CR20130616A (es) |
CY (1) | CY1117878T1 (es) |
DK (2) | DK3072886T3 (es) |
EA (2) | EA023287B1 (es) |
EC (1) | ECSP13013074A (es) |
ES (2) | ES2673614T3 (es) |
HK (1) | HK1231465A1 (es) |
HR (2) | HRP20161064T2 (es) |
HU (2) | HUE037666T2 (es) |
IL (2) | IL229685B (es) |
LT (1) | LT3072886T (es) |
MA (1) | MA35245B1 (es) |
MX (1) | MX339992B (es) |
MY (1) | MY184978A (es) |
PE (2) | PE20141583A1 (es) |
PH (1) | PH12016501375A1 (es) |
PL (2) | PL3072886T3 (es) |
PT (2) | PT3072886T (es) |
RS (2) | RS57262B1 (es) |
SG (1) | SG10201604687QA (es) |
SI (2) | SI2718266T1 (es) |
TR (1) | TR201808273T4 (es) |
TW (1) | TWI567062B (es) |
UA (1) | UA114087C2 (es) |
WO (1) | WO2012168350A1 (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9321727B2 (en) * | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
MA38218A1 (fr) | 2012-12-07 | 2016-04-29 | Hoffmann La Roche | Pyridine-2-amides utiles comme agonistes de cb2 |
EP3357918A1 (en) * | 2012-12-07 | 2018-08-08 | F. Hoffmann-La Roche AG | Novel pyridine derivatives |
UA114657C2 (uk) | 2012-12-07 | 2017-07-10 | Ф. Хоффманн-Ля Рош Аг | Піридин-2-аміди, придатні як агоністи канабіноїдного рецептора 2 |
CN104837830B (zh) | 2012-12-07 | 2018-07-20 | 霍夫曼-拉罗奇有限公司 | 作为cb2受体激动剂的吡嗪衍生物 |
CA2897513C (en) | 2013-03-07 | 2021-03-16 | F. Hoffmann-La Roche Ag | Pyrazol derivatives |
HUE036934T2 (hu) * | 2013-03-26 | 2018-08-28 | Hoffmann La Roche | Új piridin származékok |
WO2014177490A1 (en) | 2013-05-02 | 2014-11-06 | F. Hoffmann-La Roche Ag | Purine derivatives as cb2 receptor agonists |
EA028123B1 (ru) | 2013-05-02 | 2017-10-31 | Ф. Хоффманн-Ля Рош Аг | ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ АГОНИСТОВ РЕЦЕПТОРА CB2 |
EA032713B1 (ru) * | 2013-12-30 | 2019-07-31 | Лайфсай Фармасьютикалс, Инк. | Терапевтические ингибирующие соединения |
KR20180072827A (ko) * | 2014-04-04 | 2018-06-29 | 에프. 호프만-라 로슈 아게 | 카나비노이드 수용체 작용제로서 5,6-이치환된 피리딘-2-카복스아미드 |
CR20160448A (es) * | 2014-04-04 | 2016-12-14 | Hoffmann La Roche | Nuevos derivados de piridina |
CN104004006B (zh) * | 2014-05-15 | 2016-04-06 | 广州康瑞泰药业有限公司 | 一种3,6-二氢-2h-吡喃-4-硼酸频哪醇酯的合成方法 |
CN104003934B (zh) * | 2014-06-13 | 2016-04-13 | 西华大学 | 6-氯-3-氟-2-吡啶甲酸的合成 |
GB201415569D0 (en) | 2014-09-03 | 2014-10-15 | C4X Discovery Ltd | Therapeutic Compounds |
SI3364958T1 (sl) | 2015-10-23 | 2023-05-31 | Navitor Pharmaceuticals, Inc. | Modulatorji interakcije sestrina in gator2 ter njihova uporaba |
CN108368056A (zh) * | 2015-11-26 | 2018-08-03 | 豪夫迈·罗氏有限公司 | 锥虫抑制剂 |
BR112018011562B1 (pt) * | 2015-12-09 | 2023-05-02 | F. Hoffmann-La Roche Ag | Novos derivados de fenil |
GB201601703D0 (en) | 2016-01-29 | 2016-03-16 | C4X Discovery Ltd | Therapeutic compounds |
US10774064B2 (en) | 2016-06-02 | 2020-09-15 | Cadent Therapeutics, Inc. | Potassium channel modulators |
SI3571193T1 (sl) | 2017-01-23 | 2022-04-29 | Cadent Therapeutics, Inc. | Modulatorji kalijevega kanalčka |
CA3061611A1 (en) | 2017-04-26 | 2018-11-01 | Navitor Pharmaceuticals, Inc. | Modulators of sestrin-gator2 interaction and uses thereof |
CN110753690B (zh) | 2017-06-20 | 2023-12-05 | 豪夫迈·罗氏有限公司 | 吡啶衍生物 |
JP7454512B2 (ja) | 2018-06-27 | 2024-03-22 | エフ. ホフマン-ラ ロシュ アーゲー | 優先的カンナビノイド2アゴニストとしてのピリジン及びピラジン誘導体 |
MA53002A (fr) * | 2018-06-27 | 2021-05-05 | Eth Zuerich | Nouveaux composés de pyridine et de pyrazine en tant qu'inhibiteurs du récepteur cannabinoïde 2 |
JP7478672B2 (ja) * | 2018-06-27 | 2024-05-07 | エフ. ホフマン-ラ ロシュ アーゲー | カンナビノイド受容体2の阻害剤としての新規なアゼチジン置換ピリジン及びピラジン化合物 |
WO2020002314A1 (en) | 2018-06-27 | 2020-01-02 | F. Hoffmann-La Roche Ag | Radiolabeled cannabinoid receptor 2 ligand |
US20200085810A1 (en) * | 2018-07-26 | 2020-03-19 | Hoffmann-La Roche Inc. | Compounds for use in treating kidney disorders |
WO2020086456A1 (en) | 2018-10-22 | 2020-04-30 | Cadent Therapeutics, Inc. | Crystalline forms of potassium channel modulators |
US11345654B2 (en) | 2018-10-24 | 2022-05-31 | Navitor Pharmaceuticals, Inc. | Polymorphic compounds and uses thereof |
CN109665982B (zh) * | 2019-01-22 | 2022-07-08 | 深圳市第二人民医院 | 奈非西坦中间体2-吡咯烷酮的合成方法 |
MX2022005215A (es) | 2019-11-01 | 2022-06-08 | Navitor Pharm Inc | Metodos de tratamiento que usan un modulador de la diana mecanicista del complejo 1 de rapamicina (mtorc1). |
EP4125831A4 (en) * | 2020-03-23 | 2024-05-08 | Praxis Precision Medicines, Inc. | KCNT1 INHIBITORS AND METHODS OF USE |
EP4211171A2 (en) | 2020-09-10 | 2023-07-19 | Precirix N.V. | Antibody fragment against fap |
US11773088B2 (en) | 2020-11-02 | 2023-10-03 | Praxis Precision Medicines, Inc. | KCNT1 inhibitors and methods of use |
JP2024524981A (ja) * | 2021-06-24 | 2024-07-09 | レザボア ニューロサイエンス,インコーポレイテッド | Ep2アンタゴニスト化合物 |
WO2023169984A1 (en) * | 2022-03-11 | 2023-09-14 | Syngenta Crop Protection Ag | Herbicidal compounds |
WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
WO2023213801A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pre-targeting |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9005965D0 (en) | 1990-03-16 | 1990-05-09 | Shell Int Research | Herbicidal carboxamide derivatives |
GB9025828D0 (en) * | 1990-11-28 | 1991-01-09 | Shell Int Research | Herbicidal carboxamide derivatives |
ES2086579T3 (es) * | 1991-05-31 | 1996-07-01 | Sumitomo Pharma | Antagonista de leucotrieno b4. |
TW226012B (es) * | 1991-11-19 | 1994-07-01 | Dunlena Pty Ltd | |
GB2277930A (en) | 1993-05-11 | 1994-11-16 | Shell Int Research | Herbicidal picolinamide derivatives |
JP2005531520A (ja) * | 2002-03-28 | 2005-10-20 | メルク エンド カムパニー インコーポレーテッド | 置換2,3−ジフェニルピリジン類 |
FR2838438A1 (fr) | 2002-04-11 | 2003-10-17 | Sanofi Synthelabo | Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant |
AU2003265398A1 (en) | 2002-08-09 | 2004-02-25 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds and methods to modulate coagulation |
GB0222493D0 (en) | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
US20070149547A1 (en) * | 2004-02-12 | 2007-06-28 | Celine Bonnefous | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 |
KR100842135B1 (ko) * | 2004-07-21 | 2008-06-27 | 미쓰이 가가쿠 가부시키가이샤 | 디아민 유도체, 그 제조 방법 및 그것들을 유효 성분으로 하는 살균제 |
CN101155781B (zh) | 2005-04-06 | 2012-11-07 | 霍夫曼-拉罗奇有限公司 | 作为cb1逆激动剂的吡啶-3-甲酰胺衍生物 |
WO2006113261A2 (en) | 2005-04-14 | 2006-10-26 | Bristol-Myers Squibb Company | Inhibitors of 11-beta hydroxysteroid dehydrogenase type i |
WO2007011760A2 (en) * | 2005-07-15 | 2007-01-25 | Kalypsys, Inc. | Inhibitors of mitotic kinesin |
EA015820B1 (ru) | 2006-06-28 | 2011-12-30 | Глэксо Груп Лимитед | Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38 |
EP2074084B1 (en) * | 2006-09-25 | 2013-08-28 | Boehringer Ingelheim International GmbH | Compounds which modulate the cb2 receptor |
US7691863B2 (en) | 2006-10-04 | 2010-04-06 | Hoffman-La Roche Inc. | Pyrazine-2-carboxamide derivatives as CB2 receptor modulators |
US8822497B2 (en) | 2007-03-01 | 2014-09-02 | Novartis Ag | PIM kinase inhibitors and methods of their use |
SE535157C2 (sv) * | 2010-07-14 | 2012-05-02 | Fairchild Semiconductor | Konduktivitetsmodulering i en bipolär transistor i kiselkarbid |
WO2012031817A1 (en) | 2010-09-09 | 2012-03-15 | F. Hoffmann-La Roche Ag | Determination of abca1 protein levels in cells |
US9321727B2 (en) * | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
-
2012
- 2012-06-01 US US13/486,057 patent/US9321727B2/en not_active Expired - Fee Related
- 2012-06-07 SG SG10201604687QA patent/SG10201604687QA/en unknown
- 2012-06-07 TR TR2018/08273T patent/TR201808273T4/tr unknown
- 2012-06-07 ES ES16165017.1T patent/ES2673614T3/es active Active
- 2012-06-07 DK DK16165017.1T patent/DK3072886T3/en active
- 2012-06-07 CA CA2835745A patent/CA2835745A1/en not_active Abandoned
- 2012-06-07 HU HUE16165017A patent/HUE037666T2/hu unknown
- 2012-06-07 PT PT161650171T patent/PT3072886T/pt unknown
- 2012-06-07 HU HUE12725834A patent/HUE027669T2/en unknown
- 2012-06-07 DK DK12725834.1T patent/DK2718266T3/en active
- 2012-06-07 PE PE2013002773A patent/PE20141583A1/es active IP Right Grant
- 2012-06-07 RS RS20180645A patent/RS57262B1/sr unknown
- 2012-06-07 CR CR20130616A patent/CR20130616A/es unknown
- 2012-06-07 EA EA201391822A patent/EA023287B1/ru not_active IP Right Cessation
- 2012-06-07 PT PT127258341T patent/PT2718266T/pt unknown
- 2012-06-07 RS RS20160666A patent/RS55073B9/sr unknown
- 2012-06-07 PL PL16165017T patent/PL3072886T3/pl unknown
- 2012-06-07 BR BR112013031463A patent/BR112013031463A2/pt not_active Application Discontinuation
- 2012-06-07 SI SI201230619A patent/SI2718266T1/sl unknown
- 2012-06-07 MY MYPI2013702388A patent/MY184978A/en unknown
- 2012-06-07 PE PE2017002309A patent/PE20180037A1/es unknown
- 2012-06-07 JP JP2014514063A patent/JP5997265B2/ja not_active Expired - Fee Related
- 2012-06-07 CN CN201610618035.0A patent/CN106349156B/zh not_active Expired - Fee Related
- 2012-06-07 WO PCT/EP2012/060785 patent/WO2012168350A1/en active Application Filing
- 2012-06-07 SI SI201231315T patent/SI3072886T1/en unknown
- 2012-06-07 AU AU2012266369A patent/AU2012266369B2/en not_active Ceased
- 2012-06-07 LT LTEP16165017.1T patent/LT3072886T/lt unknown
- 2012-06-07 PL PL12725834.1T patent/PL2718266T3/pl unknown
- 2012-06-07 EA EA201591527A patent/EA027247B1/ru not_active IP Right Cessation
- 2012-06-07 EP EP12725834.1A patent/EP2718266B9/en not_active Not-in-force
- 2012-06-07 EP EP16165017.1A patent/EP3072886B1/en not_active Not-in-force
- 2012-06-07 UA UAA201400124A patent/UA114087C2/uk unknown
- 2012-06-07 CN CN201280028511.3A patent/CN103608332B/zh not_active Expired - Fee Related
- 2012-06-07 ES ES12725834.1T patent/ES2588327T3/es active Active
- 2012-06-07 KR KR1020147000592A patent/KR20140042848A/ko not_active Application Discontinuation
- 2012-06-07 MX MX2013014564A patent/MX339992B/es active IP Right Grant
- 2012-06-08 AR ARP120102046A patent/AR086881A1/es unknown
- 2012-06-08 TW TW101120778A patent/TWI567062B/zh not_active IP Right Cessation
-
2013
- 2013-11-28 IL IL229685A patent/IL229685B/en active IP Right Grant
- 2013-11-29 CO CO13281333A patent/CO6811864A2/es not_active Application Discontinuation
- 2013-12-05 CL CL2013003486A patent/CL2013003486A1/es unknown
- 2013-12-06 MA MA36535A patent/MA35245B1/fr unknown
- 2013-12-10 EC ECSP13013074 patent/ECSP13013074A/es unknown
-
2016
- 2016-01-21 US US15/002,681 patent/US20160137606A1/en not_active Abandoned
- 2016-07-12 PH PH12016501375A patent/PH12016501375A1/en unknown
- 2016-08-03 CY CY20161100762T patent/CY1117878T1/el unknown
- 2016-08-22 HR HRP20161064TT patent/HRP20161064T2/hr unknown
- 2016-08-25 JP JP2016164396A patent/JP6349360B2/ja not_active Expired - Fee Related
-
2017
- 2017-02-06 AU AU2017200801A patent/AU2017200801B2/en not_active Expired - Fee Related
- 2017-05-17 HK HK17104953.8A patent/HK1231465A1/zh not_active IP Right Cessation
-
2018
- 2018-01-10 IL IL256826A patent/IL256826B/en not_active IP Right Cessation
- 2018-06-04 JP JP2018106773A patent/JP6484746B2/ja not_active Expired - Fee Related
- 2018-06-08 HR HRP20180897TT patent/HRP20180897T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR086881A1 (es) | Derivados de picolinamida como agonistas del receptor cb2 | |
AR093805A1 (es) | Derivados de piridina agonistas del receptor 2 de cannabinoides | |
PE20161372A1 (es) | Inhibidores de dihidropirrolopiridina de ror-gamma | |
AR076435A1 (es) | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos | |
AR063723A1 (es) | 5-oxo-5,8-dihidro-piridopirimidinas inhibidoras de c-fms quinasas, composiciones farmaceuticas que las contienen y usos como agentes anticancer, en enfermedades cardiovasculares y procesos inflamatorios | |
PE20141691A1 (es) | Compuestos con actividad nematicida | |
MX2013007917A (es) | Derivados fusionados de aminodihidrotiazina como inhibidores de beta secretasa. | |
AR079224A1 (es) | Compuestos insecticidas basados en derivados de isoxazolina | |
AR084913A1 (es) | Derivados de aril-benzocicloalquil-amida | |
AR087919A1 (es) | Heterociclos biciclicos como inhibidores de irak4 | |
NO20084832L (no) | Pyrimidinderivater som P13K-inhibitorer | |
AR059984A1 (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa -iv para el tratamiento o prevencion de diabetes | |
ES2653265T3 (es) | Morfinanos sustituidos y el uso de éstos | |
PE20130155A1 (es) | Derivados de ariletinilo | |
AR099932A1 (es) | Derivados de piridina | |
NO20092770L (no) | Nye aminopyrimidinderivater som PLK1-inhibitorer | |
AR078168A1 (es) | Derivados de piperidinas y piperazinas, procesos para prepararlos y sus usos como moduladores de gpr119 | |
AR044795A1 (es) | Derivados de pirido [2,1-a] isoquinolina como inhibidores de la dpp-iv | |
AR054726A1 (es) | 2- fenil- indoles como antagonistas del receptor de la prostaglandina d2 | |
MY178760A (en) | Monocyclic pyridine derivative | |
MX2013005535A (es) | Compuesto de 3- (amino-aril) -piridina. | |
PE20110843A1 (es) | Derivados de 5-(1h-imidazol-5-il)-2-fenilpirimidina, como inhibidores de prostaglandina d sintasa hematopoyetica | |
AR088625A1 (es) | Derivados de aril-quinolina | |
AR060401A1 (es) | Derivados de cromen-2-ona | |
AR040626A1 (es) | Derivados de quinolina utiles como ligandos del receptor del neuropeptido y (npy) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |